Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cybin Inc. (CYBN : AMEX)

• Company Description    Cybin Inc. is a biotechnology company. It is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin Inc. is based in Toronto, Canada. Number of Employees: 50

• Price / Volume Information    Yesterday's Closing Price: $7.38 Daily Weekly Monthly 20 Day Moving Average: 371,023 shares Shares Outstanding: 23.02 (millions) Market Capitalization: $169.91 (millions) Beta: 0.69 52 Week High: $13.88 52 Week Low: $4.81 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -13.99% -17.53% 12 Week 36.16% 19.32% Year To Date -16.33% -20.97%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 100 KING STREET WEST SUITE 5600 - TORONTO,A6 M5X 1C9 CAN ph: 908-764-8385 fax: - ir@cybin.com http://www.cybin.com

• General Corporate Information    Officers Douglas Drysdale - Chief Executive Officer Eric So - President Aaron Bartlone - Chief Operating Officer Greg Cavers - Chief Financial Officer Grant Froese - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 23256X407 SIC: 2834 Fiscal Year Fiscal Year End: March Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 23.02 Most Recent Split Date: 9.00 (0.03:1) Beta: 0.69 Market Capitalization: $169.91 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.59 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.43 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.93 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 32.93% vs. Previous Quarter: -168.42% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - -37.58 ROA 06/30/25 - - 03/31/25 - - 12/31/24 - -36.59 Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - - Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©